2 completed, 1 recruiting, 1 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
Follow Sameek Roychowdhury: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging - Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Recruiting | Sameek Roychowdhury | 40 | 2025-08-26 | 2026-02-17 |
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Infigratinib - Advanced Malignant Solid Neoplasm, Cholangiocarcinoma | Phase 2 | Completed | Sameek Roychowdhury | 17 | 2020-01-16 | 2026-02-24 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression | Phase 2 | Withdrawn | Sameek Roychowdhury | 2019-03-20 | 2022-02-18 | |
| Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. ponatinib hydrochloride, laboratory biomarker analysis - Malignant Neoplasm | Phase 2 | Completed | Sameek Roychowdhury | 22 | 2015-02-24 | 2025-03-24 |
Neoplasm Metastasis (2) · Brain Neoplasms (1) · Cholangiocarcinoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Piebaldism (1)
Magnetic Resonance Spectroscopy (1) · Postmortem Imaging (1) · Tomography, Optical Coherence (1) · brigatinib (1) · infigratinib (1) · pemigatinib (1) · ponatinib (1)
United States (4)
P30CA016058 (1)